MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fuhr, U.
Right arrow Articles by Sanz, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fuhr, U.
Right arrow Articles by Sanz, F.

Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2

U Fuhr, G Strobl, F Manaut, EM Anders, F Sorgel, E Lopez-de-Brinas, DT Chu, AG Pernet, G Mahr and F Sanz

Department of Clinical Pharmacology, University Hospital Frankfurt, Germany.

The inhibitory effect of 44 quinolone antibacterials and derivatives (common structure, 4-oxoquinoline-3-carboxylic acid) on cytochrome P450 isoform CYP1A2 activity was tested using human liver microsomes and caffeine 3-demethylation as a specific test system for this enzyme. By direct comparison of molecules differing structurally in only one position, the following structure-activity relationships were found. 3'- Oxo derivatives had a reduced or similar activity and M1 metabolites (cleavage of piperazinyl substituent) had a greater inhibitory activity, compared with the parent molecule. Alkylation of the 7- piperazinyl substituent resulted in a reduced inhibitory potency. Naphthyridines with an unsubstituted piperazinyl group at position 7 displayed a greater inhibitory potency than did corresponding quinoline derivatives. Derivatives with a fluorine substitution at position 8 had only a minor effect. Molecular modeling studies with inhibitors and caffeine showed that it is possible to explain the potency of the quinolones to inhibit CYP1A2 on a molecular level. The keto group, the carboxylate group, and the core nitrogen at position 1 are likely to be the most important groups for binding to the active site of CYP1A2, because the molecular electrostatic potential of all inhibitors is very similar to that of caffeine in these regions. The presence of a piperazinyl substituent, however, seems to be no prerequisite for inhibitory potency. Finally, an equation to estimate the potency to inhibit CYP1A2 was developed by quantitative structure-activity relationship analysis.

Volume 43, Issue 2, pp. 191-199, 02/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
A. L. Upthagrove and W. L. Nelson
Importance of Amine pKa and Distribution Coefficient in the Metabolism of Fluorinated Propranolol Analogs: Metabolism by CYP1A2
Drug Metab. Dispos., November 1, 2001; 29(11): 1389 - 1395.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. Ekins, M. J. de Groot, and J. P. Jones
Pharmacophore and Three-Dimensional Quantitative Structure Activity Relationship Methods for Modeling Cytochrome P450 Active Sites
Drug Metab. Dispos., July 1, 2001; 29(7): 936 - 944.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
M. Kinzig-Schippers, U. Fuhr, M. Cesana, C. Müller, A. H. Staib, S. Rietbrock, and F. Sörgel
Absence of Effect of Rufloxacin on Theophylline Pharmacokinetics in Steady State
Antimicrob. Agents Chemother., September 1, 1998; 42(9): 2359 - 2364.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1993 by the American Society for Pharmacology and Experimental Therapeutics